Dr. Zheng is board certified in anatomic and clinical pathology with subspecialty board certification in hematopathology. She received a MD degree and subsequently a PhD degree from Beijing Medical University (currently Peking University Health Science Center) in Beijing, China. Dr. Zheng completed her residency training in anatomic and clinical pathology, followed by hematopathology fellowship training, at The Johns Hopkins School of Medicine. She has been practicing hematopathology since 2012. Before joining Labcorp, Dr. Zheng was medical director and chair of Pathology Department at Presbyterian St. Luke’s Medical Center, HCA, Denver, CO. Dr. Zheng has authored papers published in journals of Blood, Oncogene, Journal of Experimental Medicine, Leukemia, Journal of Applied Research, Leukemia research, Leukemia and Lymphoma, International Journal of Surgical Pathology and Frontiers in Pediatrics.
Areas of Support: Hematopathology
Board Certifications:
- American board of pathology: anatomic and clinical pathology
- American board of pathology: hematopathology
Memberships:
- American Society for Clinical Pathology
- United States and Canadian Academy of Pathology
PEER-REVIEWED ARTICLES
1. Meyer AK, Banks M, Nadasdy, T, Clark JJ, Zheng R, Gelfand EW and Abbott JK. Vasculitis in a Child with the Hyper-IgM Variant of Ataxia-Telangiectasia. Frontiers in Pediatrics, 2019, 7, Article 390
2. Kern JB, Hii A, Kruse MJ, Szabo Z, Argani P, Hibbard MK, Gladstone DE, Meyer C, Zheng R, Borowitz MJ and Duffield AS. A leukemic presentation of alveolar rhabdomyosarcoma in a 52-year-old woman without an identifiable primary tumor. International Journal of Surgical Pathology, 2015, 23(1):75-77.
3. Zheng R, Bailey E, Nguyen B, Yang X, Piloto O, Levis M and Small D. Further Activation of FLT3 Mutants by FLT3 Ligand. Oncogene, 2011, 30(38):4004-4014.
4. Radomska HS, Basseres DS, Zheng R, Zhang P, Dayaram T, Yamamoto Y, Sternberg DW, Lokker N, Giese NA, Bohlander SK, Schnittger S, Delmotte MH, Davis RJ, Small D, Hiddemann W, Gilliland DG, and Tenen DG. Block of C/EBP alpha function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations. Journal of Experimental Medicine, 2006, 203(2):371-381.
5. Zheng R and Small D. Mutant FLT3 signaling contributes to a block in myeloid differentiation. Leukemia and Lymphoma, 2005, 46(12):1679-1687.
6. Zheng R, Friedman AD, Levis M, Li L, Weir EG, and Small D. Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBP expression. Blood, 2004, 103(5):1883-1890.
7. Zheng R, Levis M, Piloto O, Brown P, Baldwin B, Gorin NC, Beran M, Zhu Z, Ludwig D, Hicklin D, Witte L, Li Y, and Small D. FLT3 ligand causes autocrine signaling in acute myeloid leukemia cells. Blood, 2004, 103(1):267-274.
8. Zheng R, Klang K, Gorin NC, and Small D. Lack of KIT and FMS internal tandem duplications but co-expression with ligands in AML. Leukemia Research, 2004, 28(2):121-126.
9. Levis M, Smith BD, Garrett E, Zheng R, Baldwin BR, Malehorn M, N’Guyen L, Bellal N, Allebach J, Perot C, Civin C, Gorin NC, and Small D. The clinical outcome of duplication mutations could be altered by treatment regimen. Journal of Applied Research, 2003, 3(3):296-303.
10. Lumkul R, Gorin NC, Malehorn MT, Hoehn GT, Zheng R, Baldwin B, Small D, Gore S, Smith D, Meltzer PS, and Civin C. Human AML cells in NOD/SCID mice: engraftment potential and gene expression. Leukemia, 2002, 16(9):1818-1826.
11. Levis M, Allebach J, Tse K-F, Zheng R, Baldwin B, Smith BD, Jones-Bolin S, Ruggeri B, Dionne C, and Small D. A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo. Blood, 2002, 99(11):3885-3891.
12. Zheng R, Friedman AD, and Small D. Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations. Blood, 2002, 100(12):4154-4161.
ABSTRACTS AND PRESENTATIONS
1. Willard N, Haag M, Zheng R, Lovell M. Elevated BCR-ABL1 IS in Ph(+) ALL: Laboratory Error or Biological Phenomenon? Association for Molecular Pathology Meeting, 2019
2. Zheng R, Cimino-Mathews A, Gurel B, De Marzo A.M., Hicks J and Argani P. Does PTEN loss and Activation of the mTOR Pathway Underlie Breast Cancer Metastases. United States and Canadian Academy of Pathology Annual Meeting, 2011
3. Zheng R, Yung R, Clark D, and Li QK. EBUS-TBNA Cytology of PET Positive verse PET Negative Lymph Nodes. A Retrospective Study with Histology Correlation. United States and Canadian Academy of Pathology Annual Meeting, 2010 (Platform Presentation)
4. Zheng R, Piloto O, and Small D. FLT3 Ligand Is Required for Full Activation of FLT3 Mutants.
American Society of Hematology Annual Meeting, 2006, Orlando (Oral Sessions).
5. Zheng R, Piloto O, and Small D. FLT3 Mutant activation is still dependent on FLT3 ligand. American Society of Hematology Annual Meeting, 2005, Atlanta.
6. Zheng R, Friedman AD, and Small D. Internal tandem duplication mutation of FLT3 blocks the myeloid differentiation through suppression of C/EBPa expression. American Society of Hematology Annual Meeting, 2003, San Diego.